IDO1 and pachyonychia congenita: Introducing β-CBT as a first-in-class dual inhibitor of IDO1 and DTO2 is expected to warrant future consideration of the IDO1/TDO2 axis as a novel valid molecular target to reduce the risk of PC recurrence and, therefore, improve long-term PC patients’ survival rate.